|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a child who developed a TFE3/Xp11.2 translocation renal cell carcinoma (RCC) when he was 3 years and 3 months old, after previous treatment for infantile fibrosarcoma (IFS).
|
28478739 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CA-IX is a good marker to distinguish clear cell renal cell carcinoma with TFE3 strong positive immunostaining from Xp11 translocation renal cell carcinoma.
|
31175325 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
|
30552521 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate the pathogenic mechanism of TFE3 fusions in tRCC based on its subcellular localization, nuclear translocation and transcriptional activity.
|
30849994 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
|
31043488 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using targeted RNA-sequencing, TFE3 fusion gene partners were identified in 5 cases of TFE3 immunohistochemistry positive translocation renal cell carcinoma.
|
30622287 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
|
31828108 |
2019 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations.
|
30591082 |
2018 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To demonstrate that patients with Xp11.2/TFE3 gene-fusion translocation renal cell carcinoma (RCC), despite having an aggressive course in young adults, could have valid treatment options such as mammalian target of rapamycin (mTOR) inhibitors with good outcomes.
|
29702156 |
2018 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Upregulation of PI3/AKT/mTOR pathway in additional TFE3-tRCC models was confirmed by significantly higher expression of phospho-S6 (<i>P</i> < 0.0001) and phospho-4EBP1 (<i>P</i> < 0.0001) in established tRCC cell lines compared with clear cell RCC cells.
|
30061365 |
2018 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Xp11 translocation renal cell carcinoma (RCC) with SFPQ/PSF-TFE3 gene fusion is a rare epithelial tumor.
|
28315422 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Xp11 translocation renal cell carcinoma (RCC) are defined by chromosome translocations involving the Xp11 breakpoint which results in one of a variety of TFE3 gene fusions.
|
28296677 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PRCC-TFE3 renal cell carcinoma (RCC) is one of the most common types of Xp11.2 translocation renal cell carcinoma (tRCC), of which the diagnosis mainly relies on reverse transcription-polymerase chain reaction (RT-PCR) or chromosomal analysis in fresh frozen samples.
|
28949976 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical stains performed on the nephrectomy specimen showed tumor positivity for CD10, E-cadherin, a-methylacyl coenzyme A racemase, and TFE3 supporting the diagnosis of Xp11 translocation renal cell carcinoma.
|
28185421 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the frequency of translocation renal cell carcinoma (RCC) by reverse transcription polymerase chain reaction (RT-PCR) and how well the TFE3 immunoreactivity is concordant with TFE3 gene translocation status proved by fluorescence in situ hybridization (FISH) assay and RT-PCR.
|
28415646 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Translocation renal cell carcinoma (tRCC) is a rare subtype of kidney tumour characterized by translocations involving the transcription factor TFE3 or TFEB. tRCC was introduced into the World Health Organization classification in 2004, but much is still unknown about the natural history, clinicopathological features and outcomes of the disease.
|
28106924 |
2017 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinicopathological characteristics of Xp11.2 translocation renal cell carcinoma in adolescents and adults: Diagnosis using immunostaining of transcription factor E3 and fluorescence in situ hybridization analysis.
|
26563505 |
2016 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Importantly, reverse transcriptase-PCR showed concordant results with the results of FISH assay in the 8 available frozen cases.The break-apart and ASPL-TFE3 dual-fusion FISH assay can accurately detect the translocation of the TFE3 gene and ASPL-TFE3 fusion gene and can thus serve as a valid complementary method for diagnosing Xp11.2 tRCC and ASPL-TFE3 RCC.
|
25984679 |
2015 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
|
26415891 |
2015 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
|
26045774 |
2015 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Metastatic ASPS was confirmed by demonstration of an ASPSCR1-TFE3 fusion and imaging studies that excluded metastatic Xp11.2 translocation renal cell carcinoma.
|
25268941 |
2015 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The application of TFE3 IHC stain will improve the diagnostic accuracy for detecting XP11.2 translocation renal cell carcinoma.
|
25002378 |
2014 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Review of renal carcinoma with t(6;11)(p21;q12) with focus on clinical and pathobiological aspects.
|
23426439 |
2013 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TFE3 tRCC could be clearly distinguished from the ccRCCs by RNA-Seq gene expression measurements using a previously reported tRCC gene signature.
|
24339735 |
2013 |
|
MiT family translocation renal cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results reveal genomic heterogeneity of tRCC with similarities to other renal tumor subtypes and raise important questions about the role of TFEB/TFE3 translocations and other chromosomal imbalances in tRCC biology.
|
23817689 |
2013 |